Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Renshen Yimu Wan is an approved traditional Chinese medicine (TCM) manufactured by Liaoning Jindan Pharmaceutical. It is a multi-herb formulation, typically containing Ginseng (Panax ginseng) and Motherwort (Leonurus japonicus) as its primary active components. The medication is designed to tonify Qi and nourish blood, making it a standard treatment for gynecological conditions associated with Qi and blood deficiency. Clinical indications include irregular menstruation, physical weakness, and postpartum abdominal pain. The pharmacological profile combines the adaptogenic and tonic properties of Ginseng with the uterotonic and blood-circulating effects of Motherwort. As a classic TCM formulation, it is standardized in the Chinese Pharmacopoeia and is widely used in clinical practice for regulating the menstrual cycle and supporting postpartum recovery.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on renshen yimu wan.